Allogene Therapeutics (ALLO) Long-Term Deferred Tax (2019 - 2021)

Allogene Therapeutics (ALLO) reported Long-Term Deferred Tax of $224.3 million for Q4 2021, up 315.14% sequentially from $54.0 million in Q4 2019.

Allogene Therapeutics (ALLO) Long-Term Deferred Tax (2019 - 2021) Analysis & Trends

Allogene Therapeutics (ALLO) has 2 years of Long-Term Deferred Tax data on file, last reported at $224.3 million in Q4 2021.

For the quarter ending Q4 2021, Long-Term Deferred Tax changed N/A year-over-year to $224.3 million; the trailing twelve-month figure through Dec 2021 stood at $224.3 million (changed N/A YoY), and the FY2021 full-year result was $224.3 million, changed N/A from the prior year.
Long-Term Deferred Tax improved to $224.3 million in Q4 2021, from $54.0 million in the prior quarter.
In the past five years, Long-Term Deferred Tax ranged from a high of $224.3 million in Q4 2021 to a low of $54.0 million in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Allogene Therapeutics	437.33 Mn	437.33 Mn	-

Download Data

Date	Value
Dec 31, 2021	224.25 Mn
Dec 31, 2019	54.02 Mn